Molecular biological design of novel antineoplastic therapies

Bibliography

• MILSTEIN C: With the benefit of hindsight. Inonanol (2000) 21:359–364.
   PubMedGoogle Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• •Original article that describes the discovery of mAbs.
   Google Scholar
• VAUGHAN T, OSBOURN JK, TEMPEST PR: Human antibodies by design. Biotechnol (1998) 16:535–539.
   Google Scholar
• ADAIR JR: Engineering antibodies for therapy. Intinunol Rev (1992) 130:5-40. Well-written review on the development of mAbs.
   Google Scholar
• MORRISON SL, OI VT: Genetically engineered antibody molecules. Adv. Inonanol (1989) 44:65–92.
   PubMed Web of Science ®Google Scholar
• FUNARO A, HORENSTEIN AL, MALAVASI F: Monoclonal antibodies in clinical applications. I Biol. Regal. Hoineost. Agents (1996) 10:72-82. Expert Op/n. Investig. Drugs (2004) 13(6)595
   Google Scholar
• PETERSON NC: Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies. Lab. Anim. ScL (1996) 46:8–14.
   PubMedGoogle Scholar
• BACQUIRAN DC, DANTIS L, McKERROW J: Monoclonal antibodies: innovations in diagnosis and therapy. Semin. Oncol. Nurs. (1996) 12: 30–41.
   Google Scholar
• BERKOWER I: The promise and pitfalls of monoclonal antibody therapeutics. Carr. Opin. Biotechnol. (1996) 7:622–618.
   PubMed Web of Science ®Google Scholar
• BRUMLEY CL, KUHN IA: Radiolabeled monoclonal antibodies. AORN J. (1995) 62:343–355.
   PubMedGoogle Scholar
• GRUBER R, HOLZ E, RIETHMULLER G: Monoclonal antibodies in cancer therapy. Semi]. Immunopathol. (1996) 18:243–251.
   Web of Science ®Google Scholar
• MALONEY DG: Unconjugated monoclonal antibody therapy of lymphoma. In: Monoclonal antibody-based therapy of cancer: ML Grossbard (Ed.), Marcel Dekker, New York, USA (1998):53–79.
   Google Scholar
• MOREIN HL, JUNGHANS RP: Antibody-based therapies for Hodgkin's disease. In: Monoclonal antibody-based therapy of cancer: G ML (Ed.), Marcel Dekker, New York, USA( 1998):149–188.
   Google Scholar
• RUSSELL SJ, LLEWELYN MB, HAWKINS RE: Principles of antibody therapy. Br. Med. J. (1992) 305:1424–1429.
   PubMed Web of Science ®Google Scholar
• BODEY B, BODEY BJ, SIEGEL SE: Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Carr. Pharm. Des. (2000) 6:261–276.
   PubMed Web of Science ®Google Scholar
• REITER Y, PASTAN I: Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. (1998) 16:513–520.
   PubMed Web of Science ®Google Scholar
• ESTEVA FJ, HAYES DF: Monoclonal antibody-based therapy of breast cancer. In: Monoclonal antibody-based therapy of cancer. G ML (Ed.), Marcel Dekker, NewYork (1998):309–38.
   Google Scholar
• GREEN MC, MURRAY IL, HORTOBAGYI GN: Monoclonal antibody therapy for solid tumors. Cancer Treat. Rev (2000) 26:269–286.
   PubMed Web of Science ®Google Scholar
• MURRAY IL: Monoclonal antibody treatment of solid tumors: a coming of age. Semin. Oncol. (2000) 27:64–70.
   PubMed Web of Science ®Google Scholar
• KLAPPER LN, GLATHE S, VAISMAN N: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Nati Acad. Sci. USA (1999) 96:4995–5000.
   PubMed Web of Science ®Google Scholar
• KARUNAGARAN D, TZAHAR E, BEERLI RR: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO (1996) 15:254–264.
   PubMed Web of Science ®Google Scholar
• KAPTAIN S, TAN LK, CHEN B: Her-2/neu and breast cancer. Diagn. Mol. Pathol. (2001) 10:139–152.
   PubMed Web of Science ®Google Scholar
• ROSS IS, FLETCHER JA: The HER-2/ neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells (1998) 16:413–428.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235:177–182.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GOD OLPHIN W, JONES LA: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707–712.
   PubMed Web of Science ®Google Scholar
• MUSS HB, THOR AD, BERRY DA: C-ErbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl. J. Med. (1994) 330:1260–1266.
   PubMed Web of Science ®Google Scholar
• SEIDMAN AD, BASELGA J, YAO TI: HER-2/neu overexpression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1996) 15:104.
   Google Scholar
• BRENNER TL, ADAMS VR: First mAb approved for treatment of metastatic breast cancer. J. Am. Pharm. Assoc. (1999) 39: 236–238.
   Google Scholar
• NOONBERG SB, BENZ CC: Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anti-cancer agents. Drugs (2000) 59:753–767.
   PubMed Web of Science ®Google Scholar
• LE XF, MCWATTERS A, WIENER J: Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin. Cancer Res. (2000) 6:260–270.
   PubMedGoogle Scholar
• BARNES DM, MILES DW: Response of metastatic breast cancer to trastuzumab. Lancet (2000) 355:160–161.
   PubMed Web of Science ®Google Scholar
• WHITE CA, WEAVER RL, GRILLO-LOPEZ Al: Antibody-targeted immunotherapy for treatment of malignancy. Ann. Rev Med. (2001) 52:125–145.
   PubMed Web of Science ®Google Scholar
• CARTER P, PRESTA L, GORMAN CM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Nati Acad. Sci. USA (1992) 89:4285–4289.
   PubMed Web of Science ®Google Scholar
• PEGRAM MD, BALY D, WIRTH C: Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of a humanized anti-HERZ antibody. Proc. Am. Ass. Cancer Res. (1997) 38:602.
   Google Scholar
• SLIWKOWSKI MX, LOFGREN JA, LEWIS GD: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. (1999) 26:60–70.
   PubMed Web of Science ®Google Scholar
• BASELGA J, NORTON L, ALBANELL J:Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. (1998) 58:2825–2831.
   PubMed Web of Science ®Google Scholar
• PEGRAM M, HSU S, LEWIS GD: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene (1999) 18:2241–2251.
   PubMed Web of Science ®Google Scholar
• PIETRAS RJ, PEGRAM MD, FINN RS:Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene (1998) 17:2235–2249.
   PubMed Web of Science ®Google Scholar
• BURSTEIN HJ, KUTER I, RICHARDSON PG: Herceptin and navelbine for HER2-positive metastatic breast cancer: a Phase II study. Proc. Am. Soc. Clin. Oncol. (2000) 19:102a.
   Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17:2639–2648.
   PubMed Web of Science ®Google Scholar
• VOGEL C, COBLEIGH M, TRIPATHY D: First-line, non-hormonal, treatment of women with HERZ overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HERZ antibody). Proc. Am. Soc. Clin. Oncol. (2000) 19:71a.
   Google Scholar
• VOGEL C, COBLEIGH M, TRIPATHY D: First-line single-agent Herceptin (H) therapy for women with HER2– overexpressing metastatic breast cancer (MBC). Eur. J. Cancer (2000) 36:S53.
   Google Scholar
• SEIDMAN A, FORNIER M, ESTEVA FJ: Final report: weekly Herceptin and Taxol for metastatic breast cancer: analysis of efficacy by HERZ immunophenotype (IHC) and gene amplification (FISH). Proc. Am. Soc. Clin. Oncol (2000) 19:83a.
   Google Scholar
• SLAMON D, LEYLAND-JONES B, SHAK S: Use of chemotherapy plus a monoclonal antibody against HERZ for metastatic breast cancer that overexpresses HERZ. N Engl. J. Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• ••Clinical data supporting the use ofchemotherapy plus trastuzumab.
   Google Scholar
• OSOBA D, BURCHM ORE M, ASH M: Health related quality of life (HRQL) of patients with first-line, single agent, trastuzumab (Herceptin) for metastatic HER-2 overexpressing breast cancer. Proc. Am. Soc. Clin. Oncol (2000) 19:436a.
   Google Scholar
• KUZUR ME, ALBAIN KS, HUNTINGTON MO: A Phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc. Am. Soc. Clin. Oncol (2000) 19:131a.
   Google Scholar
• SMITH G, HENDERSON JC: New treatments for breast cancer. Semin. Oncol (1996) 23:506–528.
   PubMed Web of Science ®Google Scholar
• FOSSATI R, CONFALONIERI C, TORRI V: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.," Clin. Oncol (1998) 16:3439–3460.
   Google Scholar
• MASS RD, SANDERS C, KASIAN C: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Eur: J. Cancer (2000) 36:S52.
   Google Scholar
• BASELGA J, KERRIGAN M, BURCHMORE M: Health-related quality of life (HRQL) in women with HERZ-overexpressing metastatic breast cancer (MBC) in a Phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone. Ear: .1. Cancer (1999) 35:S318.
   Google Scholar
• BASELGA J: Safety profile of herceptin (H) as a single agent and in combination with chemotherapy. Eui: J. Cancer (1999) 35:S324.
   Google Scholar
• TRIPATHY D, SLAMON D, LEYLAND-JONES B: Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial. Breast Cancer Res. Treat. (2000) 64:32.
   Google Scholar
• SAFFRAN DC, REITER RE, JAKOBOVITS A: Target antigens for prostate cancer immunotherapy. Cancer Metast Rev(1999) 18:437.
   PubMed Web of Science ®Google Scholar
• CRAFT N, SHOSTAK Y, CAREY M: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/ neu tyrosine kinase. Nat Med (1999) 5:280.
   PubMed Web of Science ®Google Scholar
• BROSSART P, STUHLER G, FLAD T: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. (1998) 58:732.
   PubMed Web of Science ®Google Scholar
• RAO JY, HEMSTREET GP 3rd, HURST RE: Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc. Natl. Acad. Sci. USA (1993) 90:8278.
   Google Scholar
• CARPENTER G, COHEN S: Epidermal growth factor. J. Biol. Chem. (1990) 265:7709–7712.
   PubMed Web of Science ®Google Scholar
• CARPENTER G: Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev Biochem. (1987) 56:881–914.
   PubMed Web of Science ®Google Scholar
• SALOMON DS, BRANDT R, CIARDIELLO F: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev Oncol Hematol (1995) 19:183–232.
   PubMed Web of Science ®Google Scholar
• GULLICK WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. (1991) 47:87–98.
   PubMed Web of Science ®Google Scholar
• LOFTS FJ, GULLICK WJ: C-erbB2 amplification and overexpression in human tumors. In: Oncogenes, and hormones: advances in cellular and molecular biology of breast cancer. RB Dickson, ME Lippman (Eds), Kluwer Academic Publishers, Boston, USA (1991):161–179.
   Google Scholar
• PREWETT M, ROCKWELL P, ROCKWELL RF: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. .1. Immunother. Emphasis Tumor Immunol (1996) 19:419–427.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, HARBISON MT, DAVIS DW: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6:1936–1948.
   PubMed Web of Science ®Google Scholar
• CHOW NH, LIU HS, LEE El: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. (1997) 17:1293.
   PubMed Web of Science ®Google Scholar
• FISCHER-COLBRIE J, WITT A, HEINZL H: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. (1997) 17:613–620.
   PubMed Web of Science ®Google Scholar
• KE LD, ADLER-STORTHZ K, CLAYMAN GL: Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck (1998) 20:320–327.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, MELHEM ME BARNES EL: Quantitative immunohistochemical analysis of transforming growth factor-a and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (1996) 78:1284–1292.
   PubMed Web of Science ®Google Scholar
• DEJONG JS, VAN DIEST PJ, VAN DER VALK P: Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. Pathol (1998) 184:53–57.
   Google Scholar
• RADINSKY R, RISIN S, FAN Z: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. (1995) 1:19–31.
   PubMed Web of Science ®Google Scholar
• NAGANE M, COUFAL F, UN H: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. (1996) 56:5079–5086.
   PubMed Web of Science ®Google Scholar
• MODJAHEDI H, AFFLECK K, STUBBERFIELD C: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in human squamous cell carcinoma HN5. hat. Oncol (1998) 13:335–342.
   Google Scholar
• HUANG S-M, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 59:1935–1940.
   PubMed Web of Science ®Google Scholar
• BASELGA J, NORTON L, MASUI H: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Natl. Cancer Inst. (1993) 85:1327–1333.
   Google Scholar
• BASELGA J, PFISTER D, COOPER MR: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Clin. Oncol. (2000) 18:904–914.
   Web of Science ®Google Scholar
• HERBST RS, ARQUETTE MA, NABELL L: Efficacy and safety of the anti-epidermal growth factor antibody (EGER) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. AACR-NCI-EORTC International Conference (2001).
   Google Scholar
• PERERA AD, KLEYMENOVA EV, WALKER CL: Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin. Cancer Res. (2000) 6: 1518.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R: Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.f Nati Cancer Inst. (1998) 90:1087.
   Google Scholar
• OCKERT D, SCHMITZ M, HAMPL M: Advances in cancer immunotherapy. bronunol. Today(1999) 20:63–65.
   PubMedGoogle Scholar
• DILLMAN RO: Magic bullets at last! Finally - approval of a monoclonal antibody for the treatment of cancer! Cancer Biother. Radiophann. (1997) 12:223–225.
   Google Scholar
• SHAN D, LEDBETTER JA, PRESS OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer bronunol. Innnunother. (2000) 48:673–683.
   PubMed Web of Science ®Google Scholar
• McLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. j. Clin. Oncol. (1998) 16:2825–2833.
   PubMed Web of Science ®Google Scholar
• •Clinical data supporting the use of rituximab in indolent lymphoma.
   Google Scholar
• PIRO LD, WHITE CA, GRILLO-LOPEZ AJ: Extended rituximab (anti-CD20 monoclonal antibody) therapy in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1999) 10:655–661.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, BURRIS HA, MORRISSEY LH: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood (2000) 95:3052–3056.
   PubMed Web of Science ®Google Scholar
• COLOMBAT P, SALLES G, BROUSSE N: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood (2001) 97:101–106.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ,WHITE CA: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti- CD20 monoclonal antibody and CHOP chemotherapy. .1 Clin. Oncol. (1999) 17:268–276.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, FALLON A, MOHR A: Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report. Blood (2001) 98:601a.
   Web of Science ®Google Scholar
• GHAZAL HH: Successful treatment of pure red cell aplasia (PRA) with rituxan in patients with CLL Blood (2001) 98:219a.
   Google Scholar
• HEGDE UP, WILSON WH, WHITE T: Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood (2002) 100:2260–2262.
   PubMed Web of Science ®Google Scholar
• WINKLER U, JENSEN M, MANZKE 0: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood (1999) 94:2217–2224.
   PubMed Web of Science ®Google Scholar
• BYRD JC, WASELENKO JK, MANEATIS TA: Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid tumor clearance. Clin. Oncol. (1999) 17:791–795.
   Web of Science ®Google Scholar
• FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endocr. Rev (1997) 18:4–25.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI Y, KITADAI Y, BUCANA CD: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55:3964–3968.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MATLI MR: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. Gin. Invest. (1995) 95:1789–1797.
   PubMed Web of Science ®Google Scholar
• TOKUNAGA T, OSHIKA Y, ABE Y: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. Cancer (1998) 77:998–1002.
   Web of Science ®Google Scholar
• BORGSTROM P, GOLD DP, HILLAN KJ: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. (1999) 19:4203–4214.
   PubMed Web of Science ®Google Scholar
• GORDON MS, MARGOLIN K, TALPAZ M: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Clin. Oncol. (2001) 19:843–850.
   Web of Science ®Google Scholar
• MARGOLIN K, GORDON MS, HOLMGREN E: Phase lb trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long- term safety data.Oncol. (2001)19:851–856.
   Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L: Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer. Clin. Oncol. (2003) 21:60–65.
   Web of Science ®Google Scholar
• ••Data that supports the use ofchemotherapy plus bevacizurnab.
   Google Scholar
• SALTZ LB, JV COX, C BLANKE: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl.' Med. (2000) 343:905–914.
   PubMed Web of Science ®Google Scholar
• DOULLIARD JY, CUNNIGHAM D, ROTH AD: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet (2000) 355:1041–1047.
   PubMed Web of Science ®Google Scholar
• PARADIS V, LAGHAV, ZEIMOURA L: Expression of vascular endothelial growth factor in renal cell carcinomas. Virchow Arch. (2000) 436:351.
   PubMed Web of Science ®Google Scholar
• YANG JC, HAWORTH L, SHERRY RM: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl. J. Med. (2003) 349:427–434.
   PubMed Web of Science ®Google Scholar
• DROLLER MJ: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J. Urol. (1998) 160:1932.
   PubMedGoogle Scholar
• INOUE K, SLATON JVV, DAVIS DW: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res. (2000) 6:2635.
   PubMed Web of Science ®Google Scholar
• KAMINISKI MS, ZASADNY KR, FRANCIS IR: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Clin. Oncol (1996) 14:1974–1981.
   Web of Science ®Google Scholar
• WITZIG TE, WHITE CA, WISEMAN GA: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. j Clin. Oncol (1999) 17:3793–3803.
   PubMed Web of Science ®Google Scholar
• PRESS OW, RASEY J: Principles of radioimmunotherapy for hematologists and oncologists. Sernin. Oncol (2000) 27:62–73.
   PubMed Web of Science ®Google Scholar
• WUN T, KWON DS, TUSCANO JM: Radioimmunotherapy: Potential as a therapeutic strategy in non-Hodgkin's lymphoma. BioDrugs (2001) 15:151–162.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Monoclonal antibodies for treating cancer. Ann. Intern. Med. (1989) 111:592–603.
   PubMed Web of Science ®Google Scholar
• WILDER RB, DENARDO GL, DENARDO SJ: Radioimmunotherapy: Recent results and future directions. J. Clin. Oncol (1996) 14:1383–1400.
   PubMed Web of Science ®Google Scholar
• ZALUTSKY MR, GARG PK, NARULA AS: Labeling monoclonal antibodies with halogen nuclides. Acta Radio] Sapp]. (1990) 374:141–145.
   PubMedGoogle Scholar
• COL CHER D: Centralized radiolabeling of antibodies for radioimmunotherapy. J. Nucl. Med. (1998) 39:11s–13s.
   Google Scholar
• KORAL KF, ZASADNY KR, KESSLER ML: CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. Nucl. Med. (1994) 35:1714–1720.
   Web of Science ®Google Scholar
• KORAL KF, LI J, DEWARAJA Y: 1–131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images. Clin. Cancer Res. (1999) 5:3004s–3009s.
   Google Scholar
• KORAL KF, DEWARAJA Y, CLARKE LA: Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report. Cancer Biother: Radiophann. (2000) 15:347–355.
   PubMed Web of Science ®Google Scholar
• CORP IP: Ibritumomab titixetan (prescribing information). IDEC Pharmaceuticals Corp., San Diego, USA (2002)
   Google Scholar
• ANDERSON WT, STRAND M: Radiolabeled antibody: Iodine versus radiometal chelates. NCI Monogr: (1987) 3:149–151.
   PubMedGoogle Scholar
• STEIN R, CHEN S, HAIM S: Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung cancer xenograft. Cancer (1997) 80:2636–2641.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, ESTES J, ZASADNY KR: Radioimmunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Update results and long-term follow-up of the University of Michigan experience. Blood (2000) 96:1259–1266.
   PubMed Web of Science ®Google Scholar
• KNOX SJ, GORIS ML, TRISLER K: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. (1996) 2:457–470.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, BEAUREGARD JC, JAMIESON M: Toxicities associated with monoclonal antibody infusions in cancer patients. Molec. Biothec (1988) 1:81–85.
   PubMedGoogle Scholar
• DILLMAN RO: Infusion reactions associated with the infusion of monoclonal antibodies in the treatment of malignancy. Cancer Metast. Rev (1999) 18:465–471.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, SHAWLER DL, SOBOL RE: Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood (1982) 59:1036–1045.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, GORDON LI, CABANILLAS F: Randomized controlled trial of yttrium-90-labeled ibritumomab titixetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol (2002) 20:2453–2463.
   PubMed Web of Science ®Google Scholar
• CHESON BD, HORNING SJ, COIFFIER B: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. Clin. Oncol (1999) 17:1244–1253.
   Web of Science ®Google Scholar
• DAVIS TA, KAMINSKI MS, JP L: Results of a randomized trial of Bexxar (tositumomab and iodine 1131 tositumomab) versus unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma. Blood (2001) 98:843a.
   Web of Science ®Google Scholar
• HORNING SJ, LUCAS JB, YOUNES A: Iodine-131 tositumomab for non-Hodgkin's lymphoma patients who progressed after treatment with rituximab: Results of a multicenter Phase II study. Blood (2000) 96:508a.
   Web of Science ®Google Scholar
• WITZIG TE, WHITE CA, FLINN IW: ZevalinTm radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma. Blood (2000) 96:507a.
   Web of Science ®Google Scholar
• LEONARD JP, FRENETTE G, DILLMAN RO: Interim safety and efficacy results of BexxarTm in a large multicenter expanded access study. Blood (2001) 98:133a.
   Web of Science ®Google Scholar
• DILLMAN RO, SHAWLER DL, McCALLISTER TJ: Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies. Cancer Biother. (1994) 9:17–28.
   PubMedGoogle Scholar
• KAMINSKI MS, ZELENETZ AD, PRESS OW: Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell lymphomas. Clin. Oncol (2001) 19:3918–3928.
   Web of Science ®Google Scholar
• WITZIG TE, WHITE CA, GORDON LI: Zevalin radioimmunotherapy can be safely administered to patients with relapsed or refractory B cell non-Hodgkin's lymphoma. Blood (2001) 98:606a.
   Web of Science ®Google Scholar
• LEUNG SO, GOLDENBERG DM, DION AS: Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. bronunol (1995) 32:1413–1427.
   Google Scholar
• DORKEN B, MOLDENHAUER G, PEZZUTTO A: HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J. Immunol. (1986) 136:4470–4479.
   PubMed Web of Science ®Google Scholar
• SATO S, TUSCANO JM, INAOKI M: CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin. Immunol. (1998) 10:287–297.
   PubMed Web of Science ®Google Scholar
• ENGEL P, NOJIMA Y, ROTHSTEIN D: The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. Immunol. (1993) 150:4719–4732.
   Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, KETAS JC: Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma. Clin. Oncol. (2003) 21:3051–3059.
   Web of Science ®Google Scholar
• •Preclinical and clinical data on the response of NHL to epratuzurnab.
   Google Scholar
• HALE G, XIA M-Q, TIGHE HP: The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 35:118–127.
   PubMed Web of Science ®Google Scholar
• GINALDI L, DE MARTINIS M, MATUTES E: Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to CAMPATH-1H. Leak. Res. (1998) 22:185–191.
   PubMed Web of Science ®Google Scholar
• OSTERBORG A, DYER MJS, BUNJES D: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. Clin. Oncol. (1997) 15:1567–1574.
   Web of Science ®Google Scholar
• KEATING MJ, FLINN I, JAIN V: Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554–3561.
   PubMed Web of Science ®Google Scholar
• PAWSON R, DYER MJS, BARGE R: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Clin. Oncol. (1997) 15:2667–2672.
   Web of Science ®Google Scholar
• RAI KR, BYRD JC, PETERSON B: A Phase II trial of fludarabine followed by alemtuzumab (CAMPATH-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901. Blood (2002) 100:205a.
   Web of Science ®Google Scholar
• LUNDIN J, KIMBY E, BJORKHOLM M: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768–773.
   PubMed Web of Science ®Google Scholar
• RIETHMULLER G, HOLZ E, SCHLIMOK G: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. (1998) 16:1788.
   PubMed Web of Science ®Google Scholar
• BRAUN S, HEPP F, KENTENICH CR: Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive cells in bone marrow. Clin. Cancer Res. (1999) 5:3999.
   PubMed Web of Science ®Google Scholar
• FOON KA, YANNELLI J, BHATTACHARYA-CHATTERJEE M: Colorectal cancer as a model for immunotherapy. Clin. Cancer Res. (1999) 5:225–236.
   PubMed Web of Science ®Google Scholar
• LAMBERT J, DEWITTE M, MARTINO HK: SB-408075 Investigator Brochure. SmithKline Beecham, Collegeville, USA (2000).
   Google Scholar
• HAGLUND C, LINDGREN J, ROBERTS PJ: Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br. Cancer (1989) 60: 845–851.
   PubMed Web of Science ®Google Scholar
• BAECKSTROM D, HANSSON GC, NILSSON 0: Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J. Biol. Chem. (1991) 266:21537–21547.
   PubMed Web of Science ®Google Scholar
• CHART RV, MARTELL BA, GROSS JL: Immunoconjugates containing novel maytansinoids: promising anti-cancer drugs. Cancer Res. (1992) 52:127–131.
   PubMed Web of Science ®Google Scholar
• CHABNER BA, LEVINE AS, JOHNSON BL: Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat. Rep. (1978) 62:429–433.
   PubMedGoogle Scholar
• BLUM RH, KAHLERT T: A Phase I study of an ansa macrolide with antitumor activity. Cancer Treat. Rep. (1978) 62:435–438.
   PubMedGoogle Scholar
• ISSELL BF, CROOKE ST: Maytansine. Cancer Treat. Rev (1978) 5:199–207.
   PubMed Web of Science ®Google Scholar
• LIU C, TADAYONI BM, BOURRET LA: Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Nati Acad. Sri. USA (1996) 93:8618–8623.
   PubMed Web of Science ®Google Scholar
• TOLCHER AW, OCHOA L, HAMMOND LA: Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the canagantigen: a phase i, pharmacokinetic, and biologic correlative study.Oncol.(2003) 21:211–222.
   Google Scholar
• •Predinical study detailing the use of immunoconjugates.
   Google Scholar
• SCHWALL RH, DUGGER SL, ERICKSON SL: Potent preclinical efficacy of Herceptin-DM1 against HERZ-overexpressing breast tumors in vivo. Clin. Cancer Res. (2001) 7:3784a.
   Google Scholar
• CHARI RVJ, STEEVES RM, XIE H: Preclinical development of huN901-DM1: A tumor activated prodrug directed against small cell lung cancer. Clin. Cancer Res. (2000) 6:4489s.
   Web of Science ®Google Scholar
• REITER RE, GU Z, WATABE T: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Nati Acad. Sri. USA (1998) 95:1735.
   PubMed Web of Science ®Google Scholar
• GU Z, THOMAS G, YAMASHIRO J: Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 19:1288.
   PubMed Web of Science ®Google Scholar
• SAFFRAN DC, RAITANO AB, HUBERT RS: Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Nati Acad. Sci. USA (2000) 98:2658.
   Web of Science ®Google Scholar
• DANNULL J, DIENER PA, PRIKLER L: Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. (2000) 60:5522.
   PubMed Web of Science ®Google Scholar
• AMARA N, PALAPATTU GS, SCHRAGE M: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. (2001) 61:4660.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A: Signal transduction therapy. A novel approach to disease mangement. Ear Biochem. (1994) 226:1–13.
   Google Scholar
• •Overview of cell signalling.
   Google Scholar
• BISHOP JM: Molecular themes in carcinogenesis. Cell (1991) 64:235–248.
   PubMed Web of Science ®Google Scholar
• GIBBS JB, OLIFF A: Pharmaceutical research in molecular oncology. Cell (1994) 79:193–198.
   PubMed Web of Science ®Google Scholar
• BOS JL, FEARON ER, HAMILTON ST: Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 327:293–297.
   PubMed Web of Science ®Google Scholar
• SMIT VT, BOOT AJM, SMITS AMM: Kras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. (1988) 16:7773–82.
   PubMed Web of Science ®Google Scholar
• RODENHUIS S, SLEBOS RJ, BOOT AJ: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. (1988) 48:5738–41.
   PubMed Web of Science ®Google Scholar
• KHOSRAVI-FAR R, DER CJ: The ras signal transduction pathway. Cancer Metast. Rev (1994) 13:67–89.
   PubMed Web of Science ®Google Scholar
• KRONTIRIS TG: Molecular medicine, oncogenes. N Engl. J. Med. (1995) 333:303–306.
   PubMed Web of Science ®Google Scholar
• PAWSON T: Protein modules and signalling networks. Nature (1995) 373:573–580.
   PubMed Web of Science ®Google Scholar
• KELLOFF GJ, LUBET RA, FAY JR: Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epid. Biom. Prey (1997) 6:267–82.
   PubMed Web of Science ®Google Scholar
• KHOSRAVI-FAR R, CAMPBELL S, ROSSMAN KL: Increasing complexity of ras signal transduction: involvement of rho family proteins. Adv. Cancer Res. (1998) 72:57–107.
   PubMed Web of Science ®Google Scholar
• GANGAROSA LM, SIZEMORE N, GRAVES-DEAL R: A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J. Biol. Chem. (1997) 272:18926–18931.
   PubMed Web of Science ®Google Scholar
• OLDHAM SM, COX AD, REYNOLDS ER: Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade. Oncogene (1998) 16:2565–2573.
   PubMed Web of Science ®Google Scholar
• LLOYD AC, OBERMUELLER F, STADDON S: Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. (1997) 11:663–677.
   PubMedGoogle Scholar
• PUMIGLIA KM, DECKER SJ: Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci USA (1997) 94:448–452.
   PubMed Web of Science ®Google Scholar
• GOUBIN F, DUCOMMUN B: Identification of binding domains on the p21Cipl cyclin-dependent kinase inhibitor. Oncogene (1995) 10:2281–2287.
   PubMed Web of Science ®Google Scholar
• WOODS D: Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cipl. MM. Cell. Biol. (1997) 17:5598–5611.
   Web of Science ®Google Scholar
• PRENDERGAST GC, KHOSRAVI-FAR R, SOLSKI PA: Critical role of Rho in cell transformation by oncogenic Ras. Oncogene (1995) 10:2289–2296.
   PubMed Web of Science ®Google Scholar
• KHOSRAVI-FAR R, SOLSKI PA, KINCH MS: Activation of Racl, RhoA, and mitogen-activated protein kinases is required for Ras transformation. MM. Cell. Biol. (1995) 15:6443–6453.
   Web of Science ®Google Scholar
• OLSON MF, PATERSON H, MARSHALL CJ: Signals from ras and rho GTPases interact to regulate expression of p2lwafl/cipl. Nature (1998) 394:295–299.
   PubMed Web of Science ®Google Scholar
• TAPAROWSKY E, SUARD Y, FASANO 0: Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (1982) 300:762–765.
   PubMed Web of Science ®Google Scholar
• REDDY EP, REYNOLDS RK, SANTOS EA: A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (1982) 300:149–152.
   PubMed Web of Science ®Google Scholar
• TABIN CJ, BRADLEY SM, BARGMANN CI: Mechanism of activation of a human oncogene. Nature (1982) 300:143–9.
   PubMed Web of Science ®Google Scholar
• TRAHEY M, McCORMICK F: A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science (1987) 238:542–545.
   PubMed Web of Science ®Google Scholar
• POLAKIS P, McCORMICK F: Interactions between p2lras proteins and their GTPase activating proteins. Cancer Surv. (1992) 12:25–42.
   PubMedGoogle Scholar
• BARBACID M: ras oncogenes: their role in neoplasia. Eur. I Clio. Inv. (1990) 20:225–235.
   PubMed Web of Science ®Google Scholar
• BARBACID m ras genes. Ann. Rev Biochem (1987) 56:779–827.
   Google Scholar
• WILLUMSEN BM, NORRIS K, PAPAGEORGE AG: Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO (1984) 3:2581–2585.
   PubMed Web of Science ®Google Scholar
• KATO K, COX AD, HISAKA MM: Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA (1992) 8:6403–6407.
   Google Scholar
• ARENDS MJ, McGREGOR AH, TOFT NJ: Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br. J. Cancer (1993) 68:1127–1133.
   PubMed Web of Science ®Google Scholar
• FERNANDES RS, McGOWAN AJ, COTTER TG: Mutant H-ras overexpression inhibits drug and UV induced apoptosis. Anticancer Res. (1996) 16:1691–1706.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC, DAVIDE JP, DESOLMS SJ: Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. MM. Cell. Biol. (1994) 14:4193–4202.
   Web of Science ®Google Scholar
• PRENDERGAST GC: Targeting farnesyltransferase: is Ras relevant? American Cancer Society, 35th Annual Meeting. Proc. KO (1999) 22–28.
   Google Scholar
• ADAMSON P, MARSHALL CJ, HALL A: Post-translational modifications of p2 lrho proteins. J. Biol. Chem. (1992) 267:20033–20038.
   PubMed Web of Science ®Google Scholar
• LEBOWITZ PF, DAVIDE JP, PRENDERGAST GC: Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with rho activity. Ma Cell. Biol. (1995) 15:6613–6622.
   Web of Science ®Google Scholar
• DU W, LEBOWITZ PF, PRENDERGAST GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. MM. Cell. Biol. (1999) 19:1831–1840.
   Web of Science ®Google Scholar
• SUZUKI N, DEL VILLAR K, TAMANOI F: Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc. Nati Acad. USA (1998) 95:10499–10504.
   PubMed Web of Science ®Google Scholar
• BORAL AL, DESSAIN S, CHABNER BA: Clinical evaluation of biologically targeted drugs: obstacles and opportunities. Cancer Chemother: Pharmacol (1998) 42(Suppl.):S3–S21.
   Google Scholar
• BARRINGTON RE, SUBLER MA, RANDS E: A farnesyl transferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. MM. Cell. Biol. (1998) 18:85–92.
   Web of Science ®Google Scholar
• LEBOWITZ PF, SAKAMURO D, PRENDERGAST GC: Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res. (1997) 57:708–713.
   PubMed Web of Science ®Google Scholar
• ADJEI AA, ERLICHMAN C, DAVIS JN: A Phase I trial of the farnesyl transferase inhibitor SCH 66336: evidence for biological and clinical activity. Cancer Res. (2000) 60:1871–1877.
   PubMed Web of Science ®Google Scholar
• ESKENS FALM, AWADA A, CUTLER DL: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. .1. Clin. Oncol (2001) 19:1167–1175.
   PubMed Web of Science ®Google Scholar
• ADJEI AA, DAVIS JN, BRUZEK LM: Synergy of the protein transferase inhibitor SCH 66336 and cisplatin in human cancer cell lines. Clin. Cancer Res. (2001) 7:1438–1445.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA A, TAUCHI T, SUMI M: Efficacy of SCH 66336, the farnesyl transferase inhibitor, against Glivec-resistant BCR-ABL-positive cells. Proc. Am. Ass. Cancer Res. (2002) 43:855.
   Google Scholar
• KARP JE, LANCET JE, KAUFMANN SH: Clinical and biologic activity of farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical-laboratory correlative trial. Blood (2001) 97:3361–3369.
   PubMed Web of Science ®Google Scholar
• •Preclinical data indicating that farnesyl transferase inhibitors have a role in haematological malignancies.
   Google Scholar
• KHURI FR, GLISSON BS, MEYERS ML: Phase I study of farnesyl transferase inhibitor 5CH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety. Clin. Cancer Res. (2000) 6:403.
   Google Scholar
• ZUJEWSKI J, HORAK ID, BOL CJ: Phase I and pharmacokinetic study of farnesyl proten transferase inhibitor R115777 in advanced cancer.' Gin. Oncol (2000) 18:927–941.
   Web of Science ®Google Scholar
• JOHNSTON SR, ELLIS PA, HOUSTON S: A Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer. Proc. Am. Ass. Clin. Oncol (2000) 19:318.
   Google Scholar
• ZHANG FL, KIRSCHMEIER P, CARR D: Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase Type I. J. Biol Chem. (1997) 272:10232–10239.
   PubMed Web of Science ®Google Scholar
• GARCIA AM, ROWELL C, ACKERMANN K: Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J. Biol. Chem. (1993) 268:18451–18458.
   Google Scholar
• JAMES GL, BROWN MS, COBB MH: Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-ras transformed Rat-1 cells but not in untransformed cells." Biol. Chem. (1994) 269:27705–27714.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor angiogenesis. In: The Molecular Bash of Cancer.. J Mendelsohn, PM Howley, MA Israel (Eds). WB Saunders, Philadelphia, USA. (1995):206–232.
   Google Scholar
• •Brief, well-written overview of angiogenesis.
   Google Scholar
• FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat. Med. (1995) 1:27–31.
   PubMed Web of Science ®Google Scholar
• HOLMGREN L, O'REILLY MS, FOLKMAN J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. (1995) 1:149–153.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353–364.
   PubMed Web of Science ®Google Scholar
• DAMERON KM, VOLPERT OV, TAINSKY MA: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 265:1582–1584.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Antiangiogenic therapy. In: Principles and practice of oncology. VT In Devita, S Hellman, SA Rosenberg (Eds). Lippincott-Raven Publishers., Philadelphia, PA, USA (1997):3075–3085.
   Google Scholar
• HANAHAN D: Signaling vascular morphogenesis and maintenance. Science (1997) 277:48–50.
   PubMed Web of Science ®Google Scholar
• KANDEL J, BOSSY-VVETZEL E, RADVANYI F: Neovascularization is associated with a switch to the export of bEGF in the multistep development of fibrosarcoma. Cell (1991) 66:1095–1104.
   PubMed Web of Science ®Google Scholar
• HOLASH J, MAISONPIERRE PC, COMPTON D: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284:1994–1998.
   PubMed Web of Science ®Google Scholar
• KUNG AL, WANG S, KLCO JM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. (2000) 6:1335–1340.
   PubMed Web of Science ®Google Scholar
• SHWEIKI D, ITIN A, SOFFER D: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359:843–845.
   PubMed Web of Science ®Google Scholar
• TAKAKURA N, WATANABE T, SUENOBU S: A role for hematopoietic stem cells in promoting angiogenesis. Cell (2000) 102:199–209.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, MASUDA H, TAKAHASHI T: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. (1999) 85:221–228.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, MUROHARA T, SULLIVAN A: Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 275:964–967.
   PubMed Web of Science ®Google Scholar
• GOMEZ-NAVARRO J, CONTRERAS JL, ARAFAT W: Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther: (2000) 7:43–52.
   PubMed Web of Science ®Google Scholar
• MASOOD R, CAI J, ZHENG T: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood (2001) 98:1904–1913.
   PubMed Web of Science ®Google Scholar
• VVEIDNER N, SEMPLE JP, VVELCH WR: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl. J. Med. (1991) 324:1–8.
   Web of Science ®Google Scholar
• VVEIDNER N: Intratumor microvessel density as a prognostic factor in cancer. Am. Pathol (1995) 147:9–19.
   PubMed Web of Science ®Google Scholar
• MILLER KD, SWEENEY CJ, SLEDGE GW Jr: Redefining the target: Chemotherapeutics as antiangiogenics. Clin. Oncol (2001) 19:1195–1206.
   Web of Science ®Google Scholar
• BROWDER T, BUTTERFIELD CE, KRALING BM: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60:1878–1886.
   PubMed Web of Science ®Google Scholar
• GRIFFON-ETIENNE G, BOUCHER Y, BREKKEN C: Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications. Cancer Res. (1999) 59:3776–3782.
   PubMed Web of Science ®Google Scholar
• BENBOW U, MAITRA R, HAMILTON JW: Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin. Cancer Res. (1999) 5:203–208.
   Web of Science ®Google Scholar
• VACCA A, LURLARO M, RIBATTI D: Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood (1999) 94:4143–4155.
   PubMed Web of Science ®Google Scholar
• SEIDMAN AD, HUDIS CA, McCAFFREY J: Dose-dense therapy with paclitaxel via weekly 1-hour infusion: Preliminary experience in the treatment of metastatic breast cancer. Semin. Oncol. (1997) 24:S17-72-S17–76.
   Google Scholar
• [No authors listed]: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. (1998) 16:301–308.
   Google Scholar
• SWEENEY CJ, MILLER KD, SISSONS SE: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. (2001) 61:3369–3372.
   PubMed Web of Science ®Google Scholar
• RAJE N, ERSON K: Thalidomide - a revival story. N Engl.' Med. (1999) 341:1606–1609.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, SHIMA Y: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 96:2943–2950.
   PubMed Web of Science ®Google Scholar
• DAMIANO JS, CRESS AE, HAZLEHURST LA: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 93:1658–1667.
   PubMed Web of Science ®Google Scholar
• UCHIYAMA H, BARUT BA, MOHRBACHER AF: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 82:3712–3720.
   PubMed Web of Science ®Google Scholar
• CHAUHAN D, UCHIYAMA H, AKBARALI Y: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-icB Blood (1996) 87:1104–1112.
   Google Scholar
• GUPTA D, TREON SP, SHIMA Y: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 15:1950–1961.
   PubMed Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E: Thalidomide is an inhibitor of angiogenesis. Proc. Nati Acad. ScL USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• VACCA A, RIBATTI D, PRESTA M: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood(1999) 93:3064–3073.
   PubMed Web of Science ®Google Scholar
• HASLETT PA, CORRAL LG, ALBERT M: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. I Exp. Med. (1998) 187:1885–1892.
   PubMed Web of Science ®Google Scholar
• DAVIES FE, RAJE N, HIDESHIMA T: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98:210–216.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl. Med. (1999) 341:1565–1571.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B, DESIKAN R, EDDLEMON P: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase II study of 169 patients. Blood (2001) 98:492–494.
   PubMed Web of Science ®Google Scholar
• WEBER DM, GAVINO M, DELASALLE K: Thalidomide alone or with dexamethasone for multiple myeloma. Blood(1999) 94:604a.
   Web of Science ®Google Scholar
• RAJKUMAR SV, FONSECA R, DISPENZIERI A: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. (2000) 75:897–901.
   PubMed Web of Science ®Google Scholar
• TSENG S, PAK G, WASHENIK K: Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Am. Acad. Dermatol. (1996) 35:969–979.
   PubMed Web of Science ®Google Scholar
• OSMAN K, COMENZO R, RAJKUMAR SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl. I Med. (2001) 344:1951–1952.
   PubMed Web of Science ®Google Scholar
• FINE HA, FIGG WD, JAECKLE K: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.J. Clin. Oncol. (2000) 18:708–715.
   PubMed Web of Science ®Google Scholar
• EISEN T, BOSHOFF C, MAK I: Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. Cancer (2000) 82:812–817.
   Web of Science ®Google Scholar
• ADLARD JW: Thalidomide in the treatment of cancer. Anticancer Drugs (2000) 11:787-791. zso. MULLER GW, CORRAL LG, SHIRE MG: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. Med. Chem. (1996) 39:3238–3240.
   Google Scholar
• MULLER GW, CHEN R, HUANG SY: Amino-substituted thalidomide analogs: potent inhibitors of TNF-a production. Bioorg. Med. Chem. Lett (1999) 9:1625-1630. zsz. MITSIADES N, MITSIADES CS, POULAKI V: Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 99:4525–4230.
   Google Scholar
• MARRIOTT JB, CLARKE IA, CZAJKA A: A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase dependent apoptosis is associated with altered expression of bc1-2 family proteins. Cancer Res. (2003) 63:593–599.
   PubMed Web of Science ®Google Scholar
• RAJE N, ERSON KC: Thalidomide and immunomodulatory drugs as cancer therapy. Carr: Opin. Oncol. (2002) 14:635–640.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on thalidomide andimmunomodulatory drugs.
   Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. Immunol. (1999) 163:380–386.
   Web of Science ®Google Scholar
• FOLKMAN J: Antiangiogenic gene therapy. Proc Nati Acad SciUSA (1998) 95:9064–9066.
   PubMed Web of Science ®Google Scholar
• PFEIFER A, KESSLER T, SILLETTI S: Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Nati Acad. Sci. USA (2000) 97:12227–12232.
   PubMed Web of Science ®Google Scholar
• DAVIDOFF AM, LEARY MA, NG CY: Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. Med. Pediam Oncol. (2000) 35:638-640. zso. GYORFFY S, PALMER K, PODOR TJ: Combined treatment of a murine breast cancer model with Type 5 adenovirus vectors expressing murine angiostatin and 0–12: A role for combined anti-angiogenesis and immunotherapy.j. Immunol. (2001) 166:6212–6217.
   Google Scholar
• NGUYEN JT, WU P, CLOUSE ME: Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. (1998) 58:5673–5677.
   Google Scholar
• CHEN QR, KUMAR D, STASS SA: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. (1999) 59:3308–3312.
   PubMed Web of Science ®Google Scholar
• LI S, ZHANG X, XIA X: Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene (2001) 3:400–407.
   Google Scholar
• FALARDEAU P, CHAMPAGNE P, POYET P: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in Phase III clinical trials. Semin. Oncol. (2001) 28:620–625.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, ECKHARDT SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J. Nati Cancer Inst. (2001) 93:178–193.
   PubMed Web of Science ®Google Scholar
• SHIFF SJ, RIGAS B: Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology (1997) 113:1992–1998.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL, JOHNSON DH: Tyrosine kinase inhibitors-ZD1839 (Iressa). Carr. Opin. Oncol. (2001) 13:491–498.
   PubMed Web of Science ®Google Scholar
• ••Brief and well written review on gefitinib.
   Google Scholar
• KIM ES, KHURI FR, HERBST RS: Epidermal growth factor receptor biology (IMC-C225). Carr. Opin. Oncol. (2001) 13:506–513.
   PubMed Web of Science ®Google Scholar
• HEYMACH JV: Angiogenesis and antiangiogenic approaches to sarcomas. Carr. Opin. Oncol. (2001) 13:261–269.
   PubMed Web of Science ®Google Scholar
• LAIRD AD, VAJKOCZY P, SHAWVER LK: 5U6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (2000) 60:4152–4160.
   PubMed Web of Science ®Google Scholar
• PERLETTI G, CONCARI P, GIARDINI R: Antitumour activity of endostatin against carcinogen-induced rat primary mammary tumours. Cancer Res. (2000) 60:1793–1796.
   PubMed Web of Science ®Google Scholar
• NIX D, PIEN C, NEWMAN R: Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Frog. Proc. Am. Soc. Gin. Oncol. (2001) 20:86a.
   Google Scholar
• KISSELEV AF, GOLDBERG AL: Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. (2001) 8:739–758.
   PubMed Web of Science ®Google Scholar
• MAKI CG, HUIBREGTSE JM, HOWLEY PM: In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. (1996) 56:2649–2654.
   PubMed Web of Science ®Google Scholar
• TATEBE H, YANAGIDA M: Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2. Carr: Biol. (2000) 10:1329–1338.
   PubMed Web of Science ®Google Scholar
• CAYROL C, DUCOMMUN B: Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene (1998) 17:2437–2444.
   PubMed Web of Science ®Google Scholar
• PAGANO M, TAM SW, THEODORAS AM: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 269:682–685.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, SCHLOSSMAN R: The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 20:4519–4527.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood (2002) 99:4079–4086.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, ERSON KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev Cancer (2002) 2:927–937.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, RICHARDSON P, CHAUHAN D: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61:3071–3076.
   PubMed Web of Science ®Google Scholar
• SUNWOO JB, CHEN Z, DONG G: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. (2001) 7:1419–1428.
   PubMed Web of Science ®Google Scholar
• FRANKE LA, MAN S, ELLIOTT P: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Gin. Cancer Res. (2000) 6:3719–3728.
   Web of Science ®Google Scholar
• TEICHER BA, ARA G, HERBST R: The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. (1999) 5:2638–2645.
   PubMed Web of Science ®Google Scholar
• BOLD RJ, VIRUDACHALAM S, McCONKEY DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S pmteasome..j Surg. Res. (2001) 100:11–17.
   PubMed Web of Science ®Google Scholar
• CUSACK JC, LIU R, HOUSTON M: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-KB inhibition. Cancer Res. (2001) 61:3535–3540.
   PubMed Web of Science ®Google Scholar
• RUSSO SM, TEPPER JE, BALDWIN AS: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-icB. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50:183–193.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, MITSIADES C, AKIYAMA M: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2003) 101:1530–1534.
   PubMed Web of Science ®Google Scholar
• RICHARDSON P, BARLOGIE B, BERENSON J: A Phase II Study of Bortezomib in Relapsed, Refractory Myeloma. N Engl. I Med. (2003) 348:2609–2617.
   PubMed Web of Science ®Google Scholar
• ••Clinical data supporting the use ofproteasome inhibitors in the treatment of MM.
   Google Scholar
• KOLIBABA KS, DRUKER BJ: Protein tyrosine kinases and cancer. Biochim. Biophys. Acta (1997) 1333:F217–F248.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, LYDON NB: Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia. Clin. Invest. (2000) 105:3–7.
   Google Scholar
• GOLDMAN JM, MELO JV: Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. J. Med. (2001) 344:1084–1086.
   PubMed Web of Science ®Google Scholar
• FADERL S, TALPAZ M, ESTROV Z, O'BRIEN S, KURZROCK R, KANTARJIAN HM: The biology of chronic myeloid leukemia. N Engl. I Med. (1999) 341:164–172.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL: Chronic myeloid leukemia. N Engl. J. Med. (1999) 340:1330–1340.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL, DRUKER BJ: Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. ScL Am. (1999) 5:63–69.
   PubMed Web of Science ®Google Scholar
• GOLDMAN JM: Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet (2000) 355:1031–1032.
   PubMed Web of Science ®Google Scholar
• SAVAGE DG, ANTMAN KH: Imatinib mesylate - a new oral targeted therapy. N Engl. J. Med. (2002) 346:683–693.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on imatinib.
   Google Scholar
• WESTBROOK CA, HOOBERMAN AL, SPINO C: Clinical significance of the BCR-
   Google Scholar
• Expert Opin. lnvestig. Drugs (2004) 13(6)
   Google Scholar
• •• ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762). Blood (1992) 80:2983–2990.
   PubMedGoogle Scholar
• ARICO M, VALSECCHI MG, CAMITTA B: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl. J. Med. (2000) 342:998–1006.
   PubMed Web of Science ®Google Scholar
• BARTRAM CR, DE KLEIN A, HAGEMEIJER A: Translocation of c-ABL oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1983) 306:277–280.
   PubMed Web of Science ®Google Scholar
• SHTIVELMAN E, LIFSHITZ B, GALE RP: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (1985) 315:550–554.
   PubMed Web of Science ®Google Scholar
• LUGO TG, PENDERGAST AM, MULLER AJ: Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science (1990) 247:1079–1082.
   PubMed Web of Science ®Google Scholar
• DALEY GQ, VAN ETTEN RA, BALTIMORE D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 247:824–830.
   PubMed Web of Science ®Google Scholar
• ELEFANTY AG, HARIHARAN IK, CORY S: BCR-ABL, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. (1990) 9:1069–1078.
   PubMed Web of Science ®Google Scholar
• DEININGER MW, VIEIRA S, MENDIOLA R: BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. (2000) 60:2049–2055.
   PubMed Web of Science ®Google Scholar
• PENDERGAST AM, QUILLIAM LA, CRIPE LD: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell (1993) 75:175–185.
   PubMed Web of Science ®Google Scholar
• PUIL L, LIU J, GISH G: BCR-ABL oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. (1994) 13:764–773.
   PubMed Web of Science ®Google Scholar
• CARPINO N, WISNIEWSKI D, STRIFE A: p62(Dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell (1997) 88:197–204.
   PubMed Web of Science ®Google Scholar
• YAMANASHI Y, BALTIMORE D: Identification of the Abl- and RasGAP- associated 62 kDa protein as a docking protein, Dok. Cell (1997) 88:205–211.
   PubMed Web of Science ®Google Scholar
• GORDON MY, DOWDING CR, RILEY GP: Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (1987) 328:342–344.
   PubMed Web of Science ®Google Scholar
• BHATIA R, VERFAILLIE CM: Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores betal integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood (1998) 91:3414–3422.
   PubMed Web of Science ®Google Scholar
• STRIFE A, LAMBEK C, WISNIEWSKI D: Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res. (1988) 48:1035–1041.
   PubMed Web of Science ®Google Scholar
• BEDI A, ZEHNBAUER BA, BARBER JP: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood (1994) 83:2038–2044.
   PubMed Web of Science ®Google Scholar
• VIGNERI P, WANG JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med (2001) 7:228–234.
   PubMed Web of Science ®Google Scholar
• SCHINDLER T, BORNMANN W, PELLICENA P: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289: 1938-1942.
   Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. J. Med. (2001) 344:1031–1037.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, SAWYERS CL, KANTARJIAN H: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl. J. Med. (2001) 344:1038–1042.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, SAWYERS C, HOCHHAUS A: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl. J. Med. (2002) 346:645–652.
   PubMed Web of Science ®Google Scholar
• TALPAZ M, SILVER RT, DRUKER B: Gleevec (formerly 5TI571): an active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase - updated results of a Phase II study. Blood (2001) 98:845a.
   Web of Science ®Google Scholar
• SAWYERS CL, HOCHHAUS A, FELDMAN E: Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: updated results of a Phase II study. Blood (2001) 98:845a.
   Web of Science ®Google Scholar
• O'BRIEN SG, GUILHOT F, LARSON RA: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl. J. Med. (2003) 348:994–1004.
   PubMed Web of Science ®Google Scholar
• ••Clinical data supporting the use of imatinib in CML.
   Google Scholar
• TALPAZ M, SILVER RT, DRUKER BJ: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99:1928–1937.
   PubMed Web of Science ®Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876–880.
   PubMed Web of Science ®Google Scholar
• LE COUTRE P, TASSI E, VARELLA-GARCIA M: Induction of resistance to the Abelson inhibitor 5TI571 in human leukemic cells through gene amplification. Blood (2000) 95: 1758-1766.
   Google Scholar
• VVEISBERG E, GRIFFIN JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor 5TI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 95:3498–3505.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL: Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Semin. Hematol (2001) 38:15–21.
   PubMed Web of Science ®Google Scholar
• THIESING JT, OHNO-JONES S, KOLIBABA KS: Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood (2000) 96:3195–3199.
   PubMed Web of Science ®Google Scholar
• FANG G, KIM CN, PERKINS CL: CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood (2000) 96:2246–2253.
   PubMed Web of Science ®Google Scholar
• HIROTA S, ISOZAKI K, MORIYAMA Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (1998) 279:577–580.
   PubMed Web of Science ®Google Scholar
• JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M: Effect of the tyrosine kinase inhibitor 5TI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl. I. Med. (2001) 344:1052–1056.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEROM AT, JUDSON I, VERWEIJ J: Safety and efficacy of imatinib (5T15 71) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358:1421–1423.
   PubMed Web of Science ®Google Scholar
• BLANKE CD, VON MEHREN M, JOENSUU H: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, 5TI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-Mt (CD117). Frog. Proc. Am. Soc. Clin. Oncol. (2001) 20:1a.
   Google Scholar
• KRYSTAL GW, HONSAWEK S, LITZ J: The selective tyrosine kinase inhibitor 5TI571 inhibits small cell lung cancer growth. Clin. Cancer Res. (2000) 6:3319–3326.
   PubMed Web of Science ®Google Scholar
• COHEN PS, CHAN JP, LIPKUNSKAYA M: Expression of stem cell factor and c-Mt in human neuroblastoma. Blood(1994) 84:3465–3472.
   PubMed Web of Science ®Google Scholar
• TONARY AM, MacDONALD EA, FAUGHT W: Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int. Cancer (2000) 89:242–250.
   PubMed Web of Science ®Google Scholar
• ARBER DA, TAMAYO R, VVEISS LM: Paraffin section deletion of the c-Mt gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum. Pathol. (1998) 29:4.
   PubMedGoogle Scholar
• WANG WL, HEALY ME, SATTLER M: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene (2000) 19:3521–3528.
   PubMed Web of Science ®Google Scholar
• KLIJN JG, BERNS PM, SCHMITZ PI: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev (1992) 13:3–17.
   PubMed Web of Science ®Google Scholar
• WOODBURN JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pbarmacol. Then (1999) 82:241–250.
   PubMed Web of Science ®Google Scholar
• AL-OBEIDI FA, LAM KS: Development of inhibitors for protein tyrosine kinases. Oncogene (2000) 19:5690–5701.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F: Epidermal growth factor receptor tyrosine kinase inhibitors as anti-Cancer agents. Drugs (2000) 60:25–32.
   PubMed Web of Science ®Google Scholar
• SIROTNAK FM, ZAKOWSKI ME MILLER VA: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6:4885–4892.
   PubMed Web of Science ®Google Scholar
• HACKEL PO, ZWICK E, PRENZEL N: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. (1999) 11:184–189.
   PubMed Web of Science ®Google Scholar
• BASELGA J, AVERBUCH SD: ZD1839 ('Iressa') as an anti-cancer agent. Drugs (2000) 60:33–40.
   PubMed Web of Science ®Google Scholar
• MOULDER SL, YAKES FM, BIANCO R: Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB-2) overexpressing breast tumor cells. Proc. Am. Soc. Clin. Oncol. (2001) 20:3a.
   Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. (2001) 7:1459–1465.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053–2063.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J, FAN Z: Epidermal growth factor receptor family and chemosensitization. J. Nati Cancer Inst. (1997) 89:341–343.
   PubMed Web of Science ®Google Scholar
• KRIS M, RANSON M, FERRY D: Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity. Clin. Cancer Res. (1999) 5(Suppl.):3749S
   Google Scholar
• MILLER VA, JOHNSON DH, HEELAN RT: A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Omni (2001) 20:326a.
   Google Scholar
• NEGORO S, NAKAGAWA K, FUKUOKA M: Final results of a Phase I intermittant dose-escalation trial of ZD1839 (Iressa) in Japanese patients with various solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 20:324a.
   Google Scholar
• KRIS MG, HERBST R, RISCHIN D: Objective regressions in non-small cell lung cancer patients treated in Phase I trials of ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer (2000) 29\(Suppl. 1):72.
   Google Scholar
• TAKETO MM: Cyclooxygenase-2 inhibitors in tumorigenesis.j Natl. Cancer Inst. (1998) 90:1529–1536.
   PubMed Web of Science ®Google Scholar
• FOSSLIEN E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. (2000) 30:3–21.
   PubMed Web of Science ®Google Scholar
• EBERHART CE, COFFEY RJ, RADHIKA A: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 107:1183–1188.
   PubMed Web of Science ®Google Scholar
• FUJITA T, MATSUI M, TAKAKU K: Size-and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. (1998) 58:4823–4826.
   PubMed Web of Science ®Google Scholar
• MILAS L: Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Omni (2001) 11:290–299.
   PubMed Web of Science ®Google Scholar
• JOKI T, HEESE 0, NIKAS DC: Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. (2000) 60:4926–4931.
   PubMed Web of Science ®Google Scholar
• KIRSCHENBAUM A, LIU X, YAO S: The role of cyclooxygenase-2 in prostate cancer. Urology (2001) 58:127–131.
   PubMed Web of Science ®Google Scholar
• YANG VW, JM SHIELDS, H SR: Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. (1998) 58:1750–1753.
   PubMed Web of Science ®Google Scholar
• BOOLBOL SK, DANNENBERG AJ, CHADBURN A: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. (1996) 56:2556–2560.
   PubMed Web of Science ®Google Scholar
• RAO CV, RIVENSON A, SIMI B et al.: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. (1995) 55:1464–1472.
   PubMed Web of Science ®Google Scholar
• KAWAMORI T, CV RAO, K SEIBERT, BS REDDY: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. (1998) 58:409–412.
   PubMed Web of Science ®Google Scholar
• SHENG H, SHAO J, MORROW JD: Modulation of apoptosis and Bc1-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. (1998) 58:362–366.
   PubMed Web of Science ®Google Scholar
• CHAN TA, MORIN PJ, VOGELSTEIN B: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl Acad. Sci. USA (1998) 95:681–686.
   PubMed Web of Science ®Google Scholar
• JONES MK, WANG H, PESKAR BM: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5:1418–1423.
   PubMed Web of Science ®Google Scholar
• TSUJII M, KAWANO S, TSUJI S: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93:705–716.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO Y, YIN M-J, UN K-M: Sulindac inhibits activation of the NF-icB pathway.' Biol. Chem. (1999) 274:27307–27314.
   Web of Science ®Google Scholar
• HE T-C, CHAN TA, VOGELSTEIN B: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 99:335–345.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM, PHILLIPS RKS: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl I Med. (2000) 342:1946–1952.
   PubMed Web of Science ®Google Scholar
• KELLOFF GJ, SIGMAN CC, GREEN WALD P: Cancer chemoprevention: Progress and promise. Eur. Cancer(1999) 35:1755–1762.
   PubMed Web of Science ®Google Scholar
• HAANEN C: Sulindae and its derivatives: a novel class of anti-cancer agents. Carr: Opin. Investig. Drugs (2001) 2:677–683.
   PubMedGoogle Scholar
• HONG SH, AVIS I, VOS MD: Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. (1999) 59:2223–2228.
   PubMed Web of Science ®Google Scholar
• GUPTA S, SRIVASTAVA M, AHMAD N: Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer (2001) 91:737–743.
   PubMed Web of Science ®Google Scholar
• MOODY TW, LEYTON J, MARTINEZ A: Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. (1998) 24:617-628. Affiliation Michel Vulfovich MD & Nabil Saba MD'r -rAuthor for correspondence Emory University School of Medicine and Winship Cancer Institute, Crawford Long Hospital, 550 Peachtree Street, Glenn Building, Atlanta, GA, USA Tel: +1 404 686 3482; E-mail: [email protected]
   Google Scholar